Syncom Formulations' Q1 Profit Soars: What's Their Secret?

Syncom Formulations, a WHO-GMP and ISO 9001:2015 certified pharmaceutical company based in Mumbai, has announced a significant surge in its Q1 profits for the fiscal year 2026-27. The company's total income for the quarter ended 30 June 2026 grew by eight percent to reach Rs.133.36 crore compared to Rs.122.94 crore in the same quarter last year.

Profit before tax increased by 59 percent to Rs.32.25 crore, while profit after tax rose by approximately 58 percent to Rs.24.85 crore. Earnings per share improved to Rs.0.26 from Rs.0.17. The Board of Directors has recommended a final dividend of Rs.0.10 per equity share for the financial year 2026. Syncom's success is attributed to its ethical, prescription-led marketing model based on strong relationships with the medical community, consistent quality manufacturing, and disciplined cost control.

The company serves various therapeutic segments including gynaecology, fertility, gastroenterology, critical care, and veterinary medicine, with a strong domestic footprint through six specialized divisions. Syncom exports to over 15 countries and holds product registrations from more than 10 international regulatory authorities.